Know Labs Innovates with New Technology Licensing Unit

Introduction to Know Labs Technology Licensing

Know Labs, Inc. (NYSE American: KNW) is thrilled to announce a significant step forward in innovation with the introduction of its newest business unit, Know Labs Technology Licensing (KTL). This initiative follows the successful framework established by companies like Qualcomm Technology Licensing. KTL is set to focus on licensing Know Labs’ intellectual property (IP) portfolio to a diverse range of partners, including corporations, academic institutions, and research organizations, effectively paving the way for advancements in the application of radio frequency dielectric spectroscopy (RFDS).

The Vision Behind KTL

The launch of KTL is a vital component of Know Labs’ strategic vision. While the primary focus of the company remains on utilizing RFDS for impactful medical diagnoses, particularly in blood glucose monitoring, KTL will also serve to leverage this technology in broader scenarios. The licensing initiative aims to enhance the functionality of RFDS technology across various sectors, including industrial processes, consumer electronics, automotive technology, and Internet-of-Things (IoT) networks.

CEO's Perspective on the Expansion

Ron Erickson, the CEO and Chairman of Know Labs, stated, “By establishing KTL, we are enhancing our reach and influence in the RFDS technology market. This initiative not only positions Know Labs at the forefront of patent licensing in advanced RF spectroscopy technology but also fosters collaborative innovation across multiple industries.”

Responding to Market Demands

Since the inception of KTL, there has been an impressive level of interest from third parties eager to investigate potential applications for RFDS technology. In light of this demand, the company has streamlined its approach to partnerships and collaborations. A notable example of this effort is a recent initiative aimed at commercializing a 'smart steering wheel' for enhancing safety features in the automotive sector, solidifying Know Labs’ position in the growing field of automotive medical IoT sensors.

Innovative Applications for RFDS Technology

The potential applications for RFDS technology are vast and varied. Know Labs envisions its technology as a sensitive detector capable of identifying changes or differences in various industrial processes. By collaborating with academic institutions and research organizations, there's an excellent opportunity to market their proprietary data collection platform for clinical research. KTL will provide Software Development Kits (SDKs) and a toolkit of RFDS test automation products to enhance collaborative efforts.

Driving Growth through Technology Licensing

KTL has two significant objectives: it aims to monetize Know Labs’ IP assets to create licensing revenues and to promote the widespread adoption of RFDS technology as an industry benchmark. This approach aligns with Know Labs’ dedication to generating shareholder value while advancing technologies that address pertinent real-world challenges. KTL is uniquely designed to cater to the significant and unsolicited demand received from various sectors.

About Know Labs, Inc.

Know Labs, Inc. is recognized as a public company on the NYSE American Exchange under the ticker symbol “KNW.” The firm specializes in utilizing radio frequency spectroscopy to analyze materials through electromagnetic energy, capturing a distinct molecular signature. This innovative technology is adaptable to numerous forms, including wearable and mobile devices. Know Labs is passionate about its commitment to revolutionize how analytes are monitored, offering a non-invasive glucose monitor among other advancements in clinical and consumer applications. Moreover, while some products developed through KTL may not necessitate prior FDA clearance, pioneering initiatives like the glucose monitor will need to secure this approval before market entry.

Frequently Asked Questions

What is Know Labs Technology Licensing?

Know Labs Technology Licensing (KTL) is a new business unit focused on licensing the RFDS technology developed by Know Labs to various partners across diverse industries.

How does KTL benefit Know Labs?

KTL allows Know Labs to generate additional revenue by monetizing its intellectual property while facilitating the adoption of RFDS technology in various applications.

What are the intended applications of RFDS technology?

RFDS technology is anticipated to be used in medical diagnostics, industrial processes, automotive safety, consumer electronics, and IoT devices, among other sectors.

Who leads Know Labs, Inc.?

Ron Erickson serves as the CEO and Chairman of Know Labs, guiding the company’s strategic initiatives and expansion efforts.

Where can I find more information about Know Labs, Inc.?

Additional information about Know Labs, Inc. can be found on their official website, where they provide insights into their technology and future developments.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. If any of the material offered here is inaccurate, please contact us for corrections.